Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.
State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.
Future Oncol. 2022 Jun;18(19):2373-2380. doi: 10.2217/fon-2021-1424. Epub 2022 Apr 20.
This study reports the outcomes of cytoreductive prostate cryoablation and metronomic cyclophosphamide for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC). Patients with mHSPC from the authors' prostate cancer database who had received cytoreductive prostate cryoablation and metronomic cyclophosphamide were identified retrospectively. Eight consecutive patients were enrolled in the study. All the patients tolerated combination therapy. The median metastatic castration-resistant prostate cancer-free survival was 62.5 months. Seven patients (87.5%) had a prostate-specific antigen nadir <0.1 ng/ml. Dysuria and hematuria before prostate cryoablation disappeared within 1 month after cryosurgery, and no incontinence was seen after prostate cryoablation. No local therapy was needed during follow-up. Cytoreductive prostate cryoablation and metronomic cyclophosphamide prove an effective and safe combination therapy for mHSPC.
本研究报告了去势敏感前列腺癌（mHSPC）患者接受前列腺冷冻消融术和节拍式环磷酰胺治疗的结果。作者从前列腺癌数据库中回顾性地确定了接受前列腺冷冻消融术和节拍式环磷酰胺治疗的 mHSPC 患者。本研究纳入了 8 例连续患者。所有患者均耐受联合治疗。中位转移性去势抵抗性前列腺癌无进展生存期为 62.5 个月。7 例患者（87.5%）前列腺特异性抗原最低值＜0.1ng/ml。前列腺冷冻消融术前的排尿困难和血尿在冷冻手术后 1 个月内消失，且前列腺冷冻消融术后无尿失禁。在随访期间无需局部治疗。前列腺冷冻消融术和节拍式环磷酰胺联合治疗 mHSPC 是一种有效且安全的治疗方法。
